Halogenated Disaccharides Enhance Biological Membrane Permeation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic agents across biological membranes, such as in the oral cavity, are inefficient, and existing antimicrobial and anti-cancer agents lack effectiveness against certain pathogens and cancers, particularly in enhancing permeation and stability for topical treatments.
Innovation Solution
Development of halogenated alkylated disaccharides and trisaccharides, specifically sucralose monolaurate and tri-chlorinated dodecyl maltose, which act as biological membrane permeation enhancers, antimicrobial agents, and anti-cancer agents, formulated in various dosage forms like oral rinses and gels to enhance therapeutic delivery and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used for delivering therapeutic agents across biological membranes, then the delivery system is simple, but the permeation efficiency is low
Solution Approach 1:
The patent introduces halogenated alkylated disaccharides as intermediary substances that facilitate the permeation of therapeutic agents across biological membranes. These compounds act as mediators that enhance the delivery efficiency without requiring complex delivery devices or systems, thus improving productivity while maintaining relative simplicity.
Solution Approach 2:
The invention modifies the chemical parameters of the delivery system by using halogenated alkylated disaccharides with specific molecular structures and properties. By changing the chemical composition and characteristics of the permeation enhancer, the patent achieves improved permeation efficiency through parameter optimization rather than system complexity.
2Reliability
If existing antimicrobial and anti-cancer agents are used, then the treatment approach is straightforward, but the effectiveness against certain pathogens and cancers is insufficient
Solution Approach 1:
The patent employs composite formulations that combine halogenated alkylated disaccharides with therapeutic agents. This composite approach creates a synergistic system where the halogenated disaccharide enhances the effectiveness of the therapeutic agent against resistant pathogens and cancers, improving reliability through material composition rather than procedural complexity.
Solution Approach 2:
The invention applies local quality enhancement by using halogenated alkylated disaccharides that specifically target and enhance permeation at the biological membrane interface. This localized action improves treatment effectiveness at the critical barrier site without requiring complex systemic formulations.
3Reliability
If simple dosage forms are used for topical treatments, then the ease of administration is high, but the stability and therapeutic delivery are insufficient
Solution Approach 1:
The patent optimizes the chemical parameters of the dosage form by incorporating halogenated alkylated disaccharides that enhance both stability and therapeutic delivery. This parameter optimization allows the maintenance of simple dosage forms like oral rinses and gels while achieving improved reliability through enhanced molecular properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds significantly enhance the permeation of therapeutic agents across biological membranes, demonstrate antimicrobial activity, and improve the effectiveness of gene therapy and diagnostic reagents, offering a more efficient and stable delivery system for topical treatments in the oral cavity and other mucosal tissues.
Implementation Method 1
halogenated alkylated disaccharides and halogenated alkylated trisaccharides used as biological membrane permeation enhancers
Implementation Method 2
demonstrate antimicrobial activity
Data Source
AI summary
The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.